Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - tipiracil hydrochloride, quantity: 7.065 mg; trifluridine, quantity: 15 mg - tablet, film coated - excipient ingredients: carnauba wax; pregelatinised maize starch; lactose monohydrate; iron oxide yellow; titanium dioxide; macrogol 8000; indigo carmine aluminium lake; hypromellose; stearic acid; iron oxide red; shellac; purified talc; magnesium stearate - colorectal cancer lonsurf is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

United States - English - NLM (National Library of Medicine)

taiho pharmaceutical co., ltd. - trifluridine (unii: rmw9v5rw38) (trifluridine - unii:rmw9v5rw38), tipiracil hydrochloride (unii: 4h59klq0a4) (tipiracil - unii:ngo10k751p) - trifluridine 15 mg - lonsurf, as a single agent or in combination with bevacizumab, is indicated for the treatment of adult patients with metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vegf biological therapy, and if ras wild-type, an anti-egfr therapy. lonsurf is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy. none. risk summary based on animal data and its mechanism of action [see clinical pharmacology (12.2)] , lonsurf can cause fetal harm. lonsurf caused embryo-fetal lethality and embryo-fetal toxicity in pregnant rats when given during gestation at doses resulting in exposures lower than or similar to human exposures at the recommended clinical dose (see data) . there are no available data on

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - trifluridine - eye drops - 10mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - trifluridine - eye drops - 10mg/1ml

Canada - English - Health Canada

bausch & lomb inc - trifluridine - solution - 1% - trifluridine 1% - antivirals

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).

Australia - English - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - decitabine, quantity: 35 mg; cedazuridine, quantity: 100 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; croscarmellose sodium; hypromellose; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350 - inqovi 35/100 is indicated for the treatment of adult patients with myelodysplastic syndromes (mds) intermediate-1, intermediate-2, and high-risk international prognostic scoring system groups, and patients with chronic myelomonocytic leukaemia (cmml).

Australia - English - Department of Health (Therapeutic Goods Administration)

servier laboratories (aust) pty ltd - trifluridine, quantity: 20 mg; tipiracil hydrochloride, quantity: 9.42 mg - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 8000; stearic acid; pregelatinised maize starch; carnauba wax; titanium dioxide; iron oxide red; purified talc; hypromellose; shellac; indigo carmine aluminium lake; iron oxide yellow; magnesium stearate - colorectal cancer orcantas is indicated for the treatment of adult patients with metastatic colorectal cancer (mcrc) who have been previously treated with, or are not considered candidates for fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti-egfr agents.,gastric cancer orcantas is indicated for the treatment of adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, her2/neu-targeted therapy.

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ferrer international - cytidine-5-disodium monophosphate + (uridine-5-trisodium triphosphate, uridine-5-disodium diphosphate, uridine-5-disodium monophosphate) - capsules - 5mg+ 3mg

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

ferrer internacional - cytidine-5-disodium monophosphate + (uridine-5-trisodium triphosphate, uridine-5-disodium diphosphate, uridine-5-disodium monophosphate) - powder lyophilized for solution for injection - 10mg+ 6mg